Introduction
============

Multidrug resistant (MDR) tuberculosis (MDR-TB), defined by resistance to at least the two frontline drugs isoniazid (INH) and rifampin (RIF), poses a significant challenge to effective treatment and control of the disease. In 2015, there were at least 480,000 cases of MDR-TB and about 9.5% of MDR-TB cases were extensively drug resistant TB, or XDR-TB ([@B19]). Drug resistance in the causative agent *Mycobacterium tuberculosis* is mainly caused by mutations affecting enzymes involved in drug activation or by alterations or overexpression of drug targets ([@B27]). However, efflux pumps, which have been found to cause antibiotic resistance in many other bacteria ([@B11]) and also non-tuberculous mycobacteria ([@B12]; [@B1]) have only recently been shown to be involved in clinical drug resistance in *M. tuberculosis* in the case of clofazimine and bedaquiline ([@B2]; [@B6]).

The efflux protein Rv1258c, also called Tap or P55, was previously shown to be involved in resistance to different drugs in overexpression studies involving *Mycobacterium megmatis* and *Mycobacterium bovis* BCG ([@B15]; [@B18]). For example, overexpression of Rv1258c was shown to confer resistance to INH, RIF, ethambutol, PAS, and ethambutol in *M. bovis* BCG ([@B15]). Additionally, [@B8] showed that Rv1258c was overexpressed upon exposure to INH and RIF in MDR-TB clinical isolates and hypothesized that its overexpression may cause drug resistance in clinical TB strains. Furthermore, various single nucleotide polymorphisms (SNPs) in different efflux pump genes Rv0194, Rv1217, Rv1258c, Rv1273, Rv1877, Rv1250, and Rv2688 in XDR-TB clinical isolates have recently been identified ([@B9]). However, the relevance of these SNPs in causing drug resistance in clinical strains has been unclear. In this study, we identified SNPs in the efflux gene *rv1258c* (*tap*) from clinical isolates of *M. tuberculosis* and then evaluated the significance of the SNPs in causing clinically relevant drug resistance by introducing these point mutations into the genome of the isogenic strain of *M. tuberculosis*. We demonstrate that mutations (V219A, S292L) in efflux pump Tap Rv1258c identified in clinical strains can cause clinically relevant drug resistance in *M. tuberculosis.*

Materials and Methods {#s1}
=====================

Bacterial Strains, Plasmids and Drugs
-------------------------------------

*Mycobacterium tuberculosis* H37Ra was grown at 37°C in Middlebrook 7H9 liquid medium or on 7H11 agar plates supplemented with 10% (v/v) albumin--dextrose--catalase (ADC, Becton Dickinson, Sparks, MD, United States) plus 0.5% (v/v) glycerol, 0.25% (v/v) Tween 80. Plasmids p2NIL and pGOAL19 used in this study were obtained from Addgene (Cambridge, MA, United States). isoniazid (INH), rifampicin (RIF), streptomycin (SM), ethambutol, pyrazinamide (PZA), levofloxacin, amikacin, cycloserine, p-aminosalicylic acid (PAS), clofazimine (CFZ), tetracycline, linezolid, clarithromycin, and piperine were purchased from Sigma-Aldrich (St Louis, MO, United States). The drugs were dissolved in DMSO and further diluted to obtain the desired concentrations in culture media for drug susceptibility testing (see below).

Construction of Rv1258c Point Mutation Mutants by Homologs Recombination
------------------------------------------------------------------------

The Rv1258c mutants were constructed in *M. tuberculosis* H37Ra by homologous recombination as described previously ([@B13]). The mutant construction and drug susceptibility testing were performed in BSL2 laboratory following institutional biosafety procedures. The reason we used the avirulent *M. tuberculosis* H37Ra strain is because it is a good surrogate of its virulent parent strain H37Rv in terms of drug susceptibility profiles ([@B7]). Briefly, the Rv1258c gene was amplified with its adjacent 1 kb fragment on both sides from *M. tuberculosis* genomic DNA and cloned into p2NIL plasmid vector. Then, the mutated constructs Rv1258c V219A and S292L were obtained by QuikChange II XL site-directed mutagenesis kit (Agilent, Santa Clara, CA, United States) with primers TPV219AF: 5′-TTCGCCTGGAACCTGCGGGTATTGCGCACCC-3′, TPV219AR: 5′-CCAGGCGAAGCGCAGCCCCTCGGCGATCCC-3′, TPS292LR: 5′-CCCCGTCGCGTGACCATGCTGACCGCGGTTCTTACCCTGGG-3′, and TPS292LR: 5′-CCCAGGGTAAGAACCGCGGTCAGCATGGTCACGCGACGGGG-3′. pGOAL19 cassette was cloned into the PacI site of p2NIL containing the mutant (V219A and S292L) version of the Rv1258c gene to form suicide delivery constructs. The suicide delivery plasmid DNA was subjected to 100 mJ/cm2 of UV irradiation followed by addition of 200 μl of electrocompetent mycobacteria. Electroporation was performed with the parameters 2.5 kV, 1000 Ω, 25 mF. The electroporated cells were added with 200 μl 7H9-Tween 80 recovery medium and incubated at 37°C for 24 h followed by plating onto 7H11/ADC plates containing kanamycin at 20 μg/ml, hygromycin at 50 μg/ml, and X-Gal at 50 μg/ml. The plates were incubated at 37°C for 4--5 weeks until colonies appeared. Single cross-over transformants were picked and re-streaked onto fresh 7H11/ADC without any antibiotics and incubated at 37°C for 2--3 weeks. A loopful of bacteria from the plates was resuspended in 1 ml of 1-mm glass beads and 3 mL of 7H9/ADC/Tween 80 and vortexed vigorously. Serial dilutions were plated onto plates containing X-gal with and without sucrose at 2% (w/v) and incubated for 4 weeks until the potential double cross-over transformants appeared. The kanamycin-sensitive colonies were screened using colony-PCR followed by DNA sequencing to confirm the desired point mutation being constructed in the genome of *M. tuberculosis* H37Ra.

Drug Susceptibility Testing and Isoniazid/Piperine Combination Studies
----------------------------------------------------------------------

The Rv1258c V219A and S292L mutants and parent strain *M. tuberculosis* H37Ra were grown in 7H9/ADC/Tween 80 medium at 37°C for 2--3 weeks \[approximately 1 × 10^8^colony-forming units (CFU)/ml\] when they were diluted in serial 10-fold dilutions and inoculated onto 7H11 agar plates containing different concentrations of drugs in triplicate. The following drug concentrations were used: SM (0.5, 1, 2, 4, and 8 μg/ml). INH (0.125, 0.25, 0.5, 1, 2, 4, 8, 16, 32, and 64 μg/ml), PZA (50, 100, 200, 400, 800, and 1600 μg/ml, pH 6.0), PAS (0.25, 0.5, 1, 2, 4, 8, 16, 32, 64, and 128 μg/ml), RIF (0.25, 0.5, 1, 2, and 4 μg/ml), ethambutol (1, 2, 4, 8, and 16 μg/ml), levofloxacin (0.25, 0.5, 1, 2, and 4 μg/ml), amikacin (0.5, 1, 2, 4, and 8 μg/ml), cycloserine (5, 10, 20, 40, and 80 μg/ml), CFZ (0.125, 0.25, 0.5, 1, and 2 μg/ml), tetracycline (0.5, 1, 2, 4, 8, 16, 32, 64, and 128 μg/ml), linezolid (0.25, 0.5, 1, 2, and 4 μg/ml), and clarithromycin (0.125, 0.25, 0.5, and 1, 2 μg/ml). The plates were incubated at 37°C in 5% CO~2~ for 3--4 weeks. The INH/piperine combination study was performed on the Rv1258c V219A and S292L mutants with different concentrations of INH tested in the presence of increasing concentrations of piperine (0, 5, 10, 20, and 40 μg/ml).

PZA Uptake and Accumulation Experiments
---------------------------------------

Two-week-old cultures of Rv1258c V219A and S292L mutants of *M. tuberculosis* H37Ra, grown in in7H9/ADC/Tween 80 medium, were harvested and the cell pellets were resuspended in 7H9 medium (pH 6.6) at 5 × 10^8^ cells/ml. The PZA uptake and accumulation study was performed as described previously ([@B25]). Briefly, \[^14^C\]PZA, purchased from Vitrax (Placentia, CA, United States), was added to the cell suspensions to a concentration of 1 μCi/ml and the cell mixtures were incubated at 37°C. At different time points, 50 μl portions were removed and washed with 1 × PBS buffer (pH 6.6) with 0.1M LiCl by filtration on 0.45 μm-pore-size nitrocellulose filters by using a vacuum pump. The amount of radioactivity associated with the bacterial cells was determined by autoradiography and scintillation counting.

Results and Discussion
======================

Identification of Point Mutations in Rv1258c From Clinical Isolates of *M. tuberculosis* and Construction of Rv1258c Point Mutations in *M. tuberculosis*
---------------------------------------------------------------------------------------------------------------------------------------------------------

To determine possible roles of efflux pumps in causing drug resistance, we performed a database search for mutations in the efflux pump Rv1258c (Tap) among clinical isolates whose whole genome sequences are deposited in the GenBank NCBI database. Several single nucleotide polymorphisms were found in the efflux gene Rv1258c (D23V, V219A, and S292L) in different clinical isolates of *M. tuberculosis*, which may affect the function of the efflux protein. This is consistent with the identification of Rv1258c P369T and G391R in XDR-TB clinical isolates from sequenced genomes of *M. tuberculosis* strains from Pakistan ([@B9]).

To address the role of the identified point mutations in Rv1258c, we attempted to construct the point mutations D23V, V219A, and S292L by site-directed mutagenesis by PCR and the altered mutant sequences were confirmed to be correct by DNA sequencing. We were able to successfully construct Rv1258c point mutations V219A and S292L, but not D23V (for unknown reasons) in *M. tuberculosis* H37Ra. It is worth noting that the constructed Rv1258c point mutation V219A and S292L mutant strains had no growth defect or altered morphology as seen in Rv1258c deletion mutant strain ([@B15]). Therefore, we evaluated the susceptibility of Rv1258c point mutation V219A and S292L mutants to various drugs as described below.

Rv1258c Point Mutations Confer Resistance to PZA, INH, and SM
-------------------------------------------------------------

The results of drug susceptibility testing showed that Rv1258c S292L mutant was more resistant to SM, INH, and PZA than the parent strain H37Ra ([Table 1](#T1){ref-type="table"}). However, Rv1258c V219A point mutation caused a lower level of resistance to the above drugs than the S292L mutation. It is noteworthy that while V219A mutation only caused a marginal level of INH resistance (MIC = 0.125 μg/ml), S292L mutation caused a very high level of INH resistance (MIC = 32 μg/ml) ([Table 1](#T1){ref-type="table"}). This latter finding is significant as it offers a possible alternative mechanism of INH resistance in addition to mutations in *katG* ([@B23]; [@B27]) or *inhA* ([@B3]). Introduction of the V219A and S292L mutations in *M. tuberculosis* did not alter the susceptibility to other drugs including RIF, ethambutol, levofloxacin, amikacin, cycloserine, PAS, CFZ, tetracycline, linezolid and clarithromycin ([Figure 1](#F1){ref-type="fig"}--[4](#F4){ref-type="fig"} and [Table 1](#T1){ref-type="table"}). Our finding that Rv1258c S292L point mutation conferred resistance to SM and INH is consistent with the previous observation of overexpression of Rv1258c ([@B15]). However, the Rv1258c S292L and V219A mutations did not alter susceptibility to other drugs such as tetracycline, RIF, EMB, CFZ, while previous studies have demonstrated that overexpression of Rv1258c could cause resistance to these drugs ([@B1]; [@B14], [@B15]). One possibility for such a discrepancy is that the point mutations at S292L and V219A cause differential binding to different drugs such that they have differential effects on causing selective drug resistance to some but not other drugs, as seen in overexpression study of the wild-type functional protein Rv1258c ([@B14], [@B15]).

###### 

Susceptibility of *M. tuberculosis* efflux pump Rv1258c point mutation mutants to different TB drugs.

  Drugs                         MIC breakpoints   Drug susceptibility results\#   
  ----------------------------- ----------------- ------------------------------- -------------------
  Isoniazid                     0.05              R (MIC 0.125 μg/ml)             R (MIC 32 μg/ml)
  Pyrazinamide                  50                R (MIC 100 μg/ml)               R (MIC 800 μg/ml)
  Streptomycin                  0.5               S                               R (MIC 4.0 μg/ml)
  Rifampin                      1.0               S                               S
  Ethambutol                    5.0               S                               S
  Amikacin                      1.0               S                               S
  Cycloserine                   10                S                               S
  p-aminosalicylic acid (PAS)   0.20              S                               S
  Clofazimine                   0.20              S                               S
  Tetracycline                  8.0               S                               S
  Linezolid                     0.5               S                               S
  Clarithromycin                2.0               S                               S
                                                                                  

\# S indicates "susceptible"; R indicates "resistant"

.

![The Rv1258c S292L mutant of *Mycobacterium tuberculosis* has higher level of resistance to streptomycin (SM) than the V219 mutant.](fmicb-10-00216-g001){#F1}

![The Rv1258c S292L mutant of *M. tuberculosis* is highly resistant to isoniazid (INH), while the V219A mutant is only slightly resistant.](fmicb-10-00216-g002){#F2}

![The Rv1258c S292L mutant of *M. tuberculosis* has a higher level of PZA resistance than the V219A mutant.](fmicb-10-00216-g003){#F3}

![The Rv1258c S292L and V219A mutants of *M. tuberculosis* remain susceptible to PAS.](fmicb-10-00216-g004){#F4}

Previous studies that evaluated drug resistance conferred by overexpression of Rv1258c did not test PZA, presumably because of the well-known problem with its susceptibility testing ([@B24]). Here, it is of interest to note that introducing the S292L point mutation in Rv1258c into the chromosome of *M. tuberculosis* conferred a high level of PZA resistance (800 μg/ml), whereas the V219A mutation caused a low level of PZA resistance (100--200 μg/ml) ([Figure 3](#F3){ref-type="fig"}). Although PZA resistance is mostly caused by *pncA* mutations ([@B26]) and less commonly by *rpsA* ([@B17])*, panD* ([@B22]), and *clpC1* ([@B20]; [@B21]) mutations, some PZA-resistant *M. tuberculosis* strains without mutations in the above known genes do exist ([@B4]) (Zhang Y, unpublished). Recently, we have shown that overexpression of efflux proteins Rv0191, Rv3756c, Rv3008, and Rv1667c could all confer low-level PZA resistance in *M. tuberculosis* ([@B28]), indicating a role of efflux in PZA resistance. However, not all efflux pumps are involved in PZA resistance as overexpression of efflux pump DrrAB in *M. tuberculosis* did not confer PZA resistance (Zhang Y, unpublished). Here it is worth noting that by constructing point mutations in the genome of the efflux pump gene *rv1258c*, we were able to convincingly demonstrate that the S292L mutation is indeed causative of PZA resistance. This finding suggests that mutations in Rv1258c could be a potential new mechanism of PZA resistance in clinical isolates without known structural gene (*pncA, rpsA, panD*) mutations. Future studies are needed to determine how frequently such mechanisms of PZA resistance mediated by mutations in Rv1258c occur in clinical isolates. Although we were able to demonstrate that the point mutations in Rv1258c confer drug resistance in *M. tuberculosis*, it remains to be determined if the mutations caused the elevated drug resistance phenotype through affecting the stability ([@B29]), expression levels ([@B10]), or drug affinity ([@B5]) of the mutant Rv1258c protein. Future studies are needed to address these possibilities.

Piperine Inhibits the INH and PZA Resistance in the Rv1258c S292L Mutant
------------------------------------------------------------------------

Piperine is a known inhibitor of efflux pump protein Rv1258c in *M. tuberculosis* ([@B16]). To determine if the S292L point mutation mediated higher level of resistance is due to elevated efflux activity of the Rv1258c S292L mutant protein, we tested if piperine could antagonize the INH and PZA resistance mediated by the Rv1258c S292L mutant protein. The piperine/INH or piperine/PZA combination study showed that piperine reduced both INH and PZA resistance or increased INH and PZA susceptibility in the Rv1258c S292L mutant *M. tuberculosis* strain ([Figure 5A,C](#F5){ref-type="fig"}), but much less so in the V219A mutant strain, presumably due to the much weaker efflux activity of the V219A mutant ([Figure 5B](#F5){ref-type="fig"}) compared with the S292L mutant. The inhibitory effect of piperine on reducing INH resistance in the V219A mutant could only be observed at a higher piperine concentration (40 μg/ml) at a low INH concentration of 0.0325 μg/ml ([Figure 5B](#F5){ref-type="fig"}). The results indicate that the higher level of INH or PZA resistance in the Rv1258c S292L mutant is caused by higher efflux activity of the S292L mutant protein that could be inhibited by piperine.

![Effect of efflux pump inhibitor Piperine on INH resistance and PZA resistance in Rv1258c mutants of *M. tuberculosis.* Piperine at 40 mg/ml but at lower concentrations inhibited or reduced the level of INH resistance **(A)** and PZA resistance **(C)** in the Rv1258c S292L mutant, but not in the V219A mutant **(B)**.](fmicb-10-00216-g005){#F5}

PZA-Resistant Rv1258c S292L Mutant Accumulates Less Drug POA
------------------------------------------------------------

It has been shown that \[^14^C\]PZA is converted to \[^14^C\]POA in *M. tuberculosis* and accumulates in the cell to some extent due to a weak efflux of POA ([@B25]). To determine if Rv1258c V219A and S292L mutants, which are confirmed to be PZA-resistant in susceptibility testing ([Figure 3](#F3){ref-type="fig"}), can pump \[^14^C\]PZA out of the cell more effectively, we performed the \[^14^C\]PZA uptake experiment comparing the amount of \[^14^C\]POA accumulated in the cell in the Rv1258c mutants and that of the control parent strain. It was found that the intracellular concentration of POA in Rv1258c mutants was lower than that of PZA-susceptible *M. tuberculosis* H37Ra ([Figure 6](#F6){ref-type="fig"}), indicating that PZA accumulated to a lesser extent in the PZA-resistant Rv1258c S292L and V219A mutants---which is an indication of higher efflux activity of the Rv1258c mutants---than the parent strain. In addition, the extent of \[^14^C\]POA accumulation was in accordance with the degree of resistance of the Rv1258c mutants, with the S292L mutant accumulating less POA than the V219A mutant, while both mutants accumulated less POA than the parent strain ([Figure 6B](#F6){ref-type="fig"}).

![Comparison of PZA/POA accumulation in Rv1258c mutants of *M. tuberculosis*. \[^14^C\]PZA was added to 5 × 10^9^ *M. tuberculosis* H37Ra and the Rv1258c mutant strains at 1 mCi/ml at pH 6.6. At different times after PZA addition, portions of bacterial cells were removed and washed by filtration using PBS (pH 6.6) as described in Methods. The results of PZA/POA accumulation are shown by autoradiography **(A)** and scintillation counting **(B)**. The S292L mutant accumulated less PZA/POA than the V219A mutant, while both mutants accumulated less drug than the parent strain *M. tuberculosis* H37Ra as shown in both **(A,B)**.](fmicb-10-00216-g006){#F6}

In conclusion, we demonstrate that point mutations in efflux pump Rv1258c found in clinical isolates can play an important role in conferring clinically relevant drug resistance to multiple drugs including PZA, SM and INH. Our findings could explain some previously unaccounted drug resistance in drug-resistant clinical strains and indicate efflux pump mutations may need to be taken into consideration for improved molecular detection of drug resistance in *M. tuberculosis*. Furthermore, efflux pump inhibitor piperine may be used as adjunct for more effective possible treatment of multi-drug resistant *M. tuberculosis* in future studies.
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